Table S1 The patient characteristics between neoadjuvant chemotherapy and Neoadjuvant immunotherapy

Variable	ICI	No-ICI	p
Total	53	55	
Age (years), mean	63.4±6.36	65.13±5.62	>0.99
Sex			
Male	52	48	0.06
Female	1	7	
Cycles of neoadjuvant chemotherapy	2.40±0.82	2.27±0.76	0.1
Pathology			0.2
Squamous	50	48	
Adenosquamous	0	3	
Large cell lung cancer	0	2	
Other type*	3	2	
Pulmonary ventilation function			0.8
Normal	18	30	
Obstructive	27	27	
Restrictive	3	5	
Mixed	6	3	
ventilation function			0.7
Normal	18	20	
Mild/moderate	31	33	
Moderate-to-severe/severe	4	2	
Surgical method			0.11
Video-assisted thoracic surgery	46	41	
Thoracotomy	7	14	
Lung lobes removed			0.5
<1 lung lobe	8	5	
1 lung lobe	34	35	
>1 lung lobe	11	15	

ICI, immune checkpoint inhibitor. *, including 2 non-small cell lung cancer not-otherwise specified patients, 2 poor differentiated lung cancer patients, and 1 squamous cell carcinoma combined with sarcomatoid carcinoma patient.

Table S2 The different immune checkpoint inhibitors and PPCs

Variable	Non-PPC	PPC	P
Pembrolizumab	12	8	0.07
Tislelizumab	5	0	
Camrelizumab	8	7	
Sintilimab	9	2	
Toripalimab	0	2	

PPC, postoperative pulmonary complication.